Date | Price Target | Rating | Analyst |
---|---|---|---|
11/29/2021 | $12.00 | Buy | Maxim Group |
Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted business TV show, announces episode 591, airing on the Fox Business Network tonight, Monday, August 26, 2024, at 10:30 PM PT. New to The Street's 591st TV episode line-up features the following five (5) Corporate interviews: 1). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO. 2). "Game Changers" segment interview with Iagon's (CRYPTO: IAG) ($IAG) Dr. Navjit Dhaliwal, CEO. 3). "Game Changers" segment interview with GreenLite Ventures, Inc.'s (OTC:GRNL) ($GRNL) (No Limit Technology Holdings, Inc.) Rafael Groswirt, CEO 4). Sustainable Solu
September 9-11, 2024 STATEN ISLAND, N.Y., Aug. 26, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand. David P. Luci, President & CEO of the Company, will provide an overview of the Company's business during the presentation. If you are an institutional
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a national business TV show, announces episode 590, airing on the FOX Business Network, tonight Monday, August 19, 2024, at 10:30 PM PT. New to The Street's 590th episode line-up features the following five (5) Corporate interviews: 1). Two-Wheel Electric Vehicle (EV) - Zapp Electric Vehicles Group Limited's (NASDAQ:ZAPP) ($ZAPP) Mark Kobal, Head of Investor Relations. 2). Biopharmaceutical - Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) David Luci, President/CEO. 3). Real Estate - La Rosa Holdings Corp's. (NASDAQ:LRHC) ($LRHC) Joe La Rosa, Founder/CEO, and Deana La Rosa, Ch
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
10-Q - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)
SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)
Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved
STATEN ISLAND, N.Y., Aug. 9, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2024. Highlights of the second quarter ended June 30, 2024, or in some cases shortly thereafter, include: In April 2024, we completed a successful End-of-Phase 2 Clinical Meeting with FDA and confirmed Phase 3 Readiness for ibezapolstat (IBZ) to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement with FDA was reached
STATEN ISLAND, N.Y., July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its second quarter 2024 financial results on Friday, August 9, 2024 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Friday, August 9, 2024 Time: 8:00 a.m. ET Toll free (U.S
STATEN ISLAND, N.Y., May 15, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2024. Highlights of the first quarter ended March 31, 2024, or in some cases shortly thereafter, include: On January 17, 2024, we announced positive comparative microbiology and microbiome data for ibezapolstat in CDI patients from the Phase 2b clinical trial segment. Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile a